enGene reports 54% response rate in bladder cancer gene therapy trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 7, 2026 7:00 AM EDT54% complete response (CR) rate at any time; 43% sixmonth CR rate
Low rate of progression to muscle-invasive or higher disease (3.2%)
Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), nearly all of which were mild
Low percentage of patients experienced TRAEs leading to treatment interruption (2.4%) or discontinuation (2.4%)
Kaplan-Meier estimate of 12-month CR rate is 25%
enGene to host webcast to discuss results today, May 7, 2026, at 8:00 a.m. ET
BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Therapeutics Inc.... More
